Partnering
Business Development
Partnerships and collaborations are a key part of HiFIBiO’s strategy.
We are open to flexible partnership models - out-licensing, development and research collaborations, academic alliances - to maximize the potential of our novel pipeline candidates and to harness the power of our proprietary Drug Intelligence Science (DIS®) platform.
Our DIS® approach provides a uniquely flexible single cell solution for target, antibody, and biomarker discovery.
Areas of interest
Pipeline
Robust product portfolio focused on immune modulation to treat cancer and autoimmune diseases
- Out-license of select pipeline assets for global development and commercialization
- Collaborations to explore novel combinations with HiFiBiO's pipeline assets
- Collaborations to identify and develop novel therapeutic antibodies
Platform
Proprietary Drug Intelligence Science (DIS®) approach provides a uniquely flexible single cell solution for target, antibody, and biomarker discovery
- Indication selection and biomarker discovery for advanced patient stratification
- Discovery and validation of novel therapeutic targets
- Translational analysis of HiFiBiO's single-cell database
Pipeline
Robust product portfolio focused on immune modulation to treat cancer and autoimmune diseases
- Out-license of select pipeline assets for global development and commercialization
- Collaborations to explore novel combinations with HiFiBiO's pipeline assets
- Collaborations to identify and develop novel therapeutic antibodies
Platform
Proprietary Drug Intelligence Science (DIS®) approach provides a uniquely flexible single cell solution for target, antibody, and biomarker discovery
- Indication selection and biomarker discovery for advanced patient stratification
- Discovery and validation of novel therapeutic targets
- Translational analysis of HiFiBiO's single-cell database
Please contact our Business Development Team.